Clinical trials: Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Myeloid malignancies which include AML (acute myeloid leukemia) and MDS (myelodysplatic syndrome) are cancers of the bone marrow which lead to bone marrow failure.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05184842
- Testing
- Venetoclax, Decitabine
- Where
- 3 sites in United States
- Volunteers
- 91 people
- Sponsor
- Montefiore Medical Center
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Leukemia, Lymphoma
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00301951
- Testing
- anti-thymocyte globulin, sargramostim, busulfan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Paroxysmal Nocturnal Hemoglobinuria, Natural History Study
Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China
This is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis.
- Trial name
- NCT05125341
- Where
- China
- Volunteers
- 67 people
- Sponsor
- CARE Pharma Shanghai Ltd.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
The purpose of this study is to evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units meeting a predetermined total minimum cell dose of 2.0 x 10 to the seventh total nucleated cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non-Hodgkin Lymphoma
- Trial name
- NCT00328237
- Testing
- Cord Blood Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Colorado Blood Cancer Institute
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Patients eligible for a mismatch allogeneic stem cell transplant will receive Venetoclax daily for 7 days prior to transplant in addition to the following chemotherapy regimen: Decitabine daily for 5 days, Fludarabine daily for 5…
- Trial name
- NCT06337331
- Testing
- Venetoclax, Decitabine, Fludarabine
- Where
- United States
- Sponsor
- Northside Hospital, Inc.
Leukemia, Lymphoma
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care…
- Conditions
- Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT05745285
- Testing
- LLS Program
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Miami
Myelodysplastic Syndromes
A Study of Galunisertib in Participants With Myelodysplastic Syndromes
The purpose of this study is to investigate the effect of the study drug known as galunisertib in participants with myelodysplastic syndromes (MDS).
- Trial name
- NCT02008318
- Testing
- Galunisertib
- Where
- 14 sites in Germany, Italy and 1 more
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Myelodysplasia, Hematologic Malignancy
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+…
- Trial name
- NCT03431090
- Testing
- CliniMACS® TCRαβ/CD19 Combined Depletion System
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Leukemia, Myelodysplastic Syndromes
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00253513
- Testing
- fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
Caris Chromoseq Data Collection
The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Myelodysplatic Syndromes, Myeloproliferative Neoplasm
- Trial name
- NCT07680868
- Testing
- Caris Chromoseq
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Caris Science, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
This study aims at evaluating the safety of an approach based on HLA-mismatched Microtransplantation without immunosuppressive treatment in patients With myeloid hemopathies who are ineligible to conventional allograft
- Trial name
- MICROSTEM (NCT03232268)
- Testing
- HLA-mismatched microtransplantation
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Institut Paoli-Calmettes
Kidney Cancer, Leukemia
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease
RATIONALE: A bone marrow transplant from a brother or sister may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00118326
- Testing
- filgrastim, allogeneic bone marrow transplantation
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndrome
Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
This is an extension study to investigate long term safety and efficacy of SyB C-1101 when orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who have completed 6 cycles in the study 2012002…
- Trial name
- NCT02002936
- Testing
- SyB C-1101
- Where
- 4 sites in Japan
- Volunteers
- 1 people
- Sponsor
- SymBio Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01794299
- Testing
- ATIR
- Where
- 8 sites in Belgium, Canada and 2 more
- Volunteers
- 31 people
- Sponsor
- Kiadis Pharma
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005092
- Testing
- Cyclophosphamide, Psoralen, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Paroxysmal Nocturnal Hemoglobinuria
Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria
This clinical study is a randomized, open-label, international, multi-center, comparative study of efficacy and safety of BCD-148 and Soliris® in PNH patients.
- Trial name
- NCT04060264
- Testing
- BCD-148, Soliris
- Where
- Russia
- Volunteers
- 28 people
- Sponsor
- Biocad
Myelodysplastic Syndrome, Myelodysplastic Syndromes
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
This is a Phase I/II, open-label, 2 arm study to evaluate the safety and clinical activity of GSK2879552 alone, or in combination with azacitidine in subjects with MDS. The study consisted of 2 parts.
- Trial name
- NCT02929498
- Testing
- GSK2879552, Azacitidine
- Where
- 6 sites in United States, Spain
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Myelodysplastic Syndromes (MDS)
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
This study aims to collect real-world data on treatment patterns and clinical outcomes for participants who discontinued Luspatercept or epoetin alfa treatment and discontinued the COMMANDS trial (NCT03682536) utilizing existing…
- Trial name
- NCT06581055
- Testing
- Luspatercept, Epoetin Alfa
- Where
- Taiwan
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.